A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer

Cancer Biology and Therapy

Volumn 3, Issue 1, 2004, Pages 89-93

  Hobdy, Erole M ^a   Kraut, Eric ^b   Masters, Gregory ^c   Blum, Kathleen ^a   McKeon, Anne ^a   Byrd, Boyd ^a   Davies, Marianne ^a   Beaulieu, Nancy ^a   Murren, John R ^a,d  

^a YALE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclophosphamide; Small cell lung cancer; Topotecan

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BACTEREMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; HYPONATREMIA; LUNG SMALL CELL CANCER; MALE; MORBIDITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; REMISSION; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; SEIZURE; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING; FOLLOW UP; LUNG TUMOR; MIDDLE AGED; MORTALITY; SMALL CELL CARCINOMA; SURVIVAL; SURVIVOR; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CYCLOPHOSPHAMIDE; FEMALE; FILGRASTIM; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 3142583722     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.1.600     Document Type: Article

References (18)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
2. Zelen M. Keynote address on biostatistics and data retrieval, part 3. Cancer chemother Rep 1973; 4:31-2.
3. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J Clin Oncol 1999; 17:1794-801.
4. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J Clin Oncol 1995; 13:1215-20.
5. Argiris A, Murren JR. Advances in chemotherapy for small-cell lung cancer: Single agent activity of newer agents. Cancer J 2001; 7:228-35.
6. Murren JR, Glatstein E, Pass HI. Small cell lung cancer. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principle and Practice of Oncology. 6th ed. Philadelphia, Lippincott: Williams and Wilkins, 2001:938-1018.
7. Liu LF, Duann P, Lin CT, D'Arpa P, Wu J. Mechanism of action of camptothecin. Ann NY Acad Sci 1996; 803:44-9.
8. Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J. Phase II study of topotecan in extensive stage small cell lung cancer. J Clin Oncol 1996; 14:2345-52.
9. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-67.
10. Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, et al. Dose escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory malignancies. J Clin Oncol 1997; 15:148-57.
11. WHO handbook for reporting the results of cancer treatment. Geneva: World Health Organization, 1979.
12. Lassen UN, Hirsch FR, Osterlind K, Bergman B, Dombernowsky P. Outcome of combination chemotherapy in extensive stage small-cell lung cancer: Any treatment related progress? Lung Cancer 1998; 20:151-60.
13. Sundstrom S, Bremnes RM, Kassa S, Aasebo U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years follow-up. J Clin Oncol 2002; 20:4665-72.
14. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The european organization for research and treatment of cancer early clinical studies group and new drug development office and the lung cancer cooperative group. J Clin Oncol 1997; 15:2090-6.
15. Lassen UN, Osterlind K, Hirsch FR, Bergman B, Dombernowsky P, Hansen HH. Early death during chemotherapy in patients with small-cell lung cancer:derivation of a prognostic index for toxic death and progression. Br J Cancer 1999; 79:515-9.
16. Morittu L, Earl HM, Souhami RL, Ash CM, Tobias JS, Geddes DM, et al. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer 1989; 59:801-4.
17. Radford JA, Ryder WDJ, Dodwell D, Anderson H, Thatcher N. Predicting septic complications from chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 1993; 29A:81-6.
18. Stephens RJ, Girling DJ, Machin D. Treatment-related deaths in small cell lung cancer trials:Can patients at risk be identified? Medical Research Council Lung Cancer Working Party. Lung Cancer 1994; 11:259-74.